- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01620190
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To evaluate the overall response rate of weekly nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations following front-line therapy with EGFR tyrosine kinase inhibitors (TKI).
SECONDARY OBJECTIVES:
I. To evaluate the safety profile of weekly nab-paclitaxel in patients with advanced NSCLC with EGFR mutations following front-line therapy with an EGFR TKI.
II. To evaluate the time-to-progression and overall survival.
OUTLINE:
Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks and then every 3 months thereafter.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Alaska
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Vereinigte Staaten, 99508
- Providence Alaska Medical Center
-
-
Montana
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Bozeman Deaconess Hospital
-
-
Washington
-
Kennewick, Washington, Vereinigte Staaten, 99336
- Kadlec Clinic Hematology and Oncology
-
Mount Vernon, Washington, Vereinigte Staaten, 98274
- Skagit Valley Hospital
-
Port Angeles, Washington, Vereinigte Staaten, 98362
- Olympic Medical Center
-
Redmond, Washington, Vereinigte Staaten, 98052
- Group Health Cooperative
-
Seattle, Washington, Vereinigte Staaten, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
Spokane, Washington, Vereinigte Staaten, 99216
- Spokane Valley Cancer Center-Mission
-
Tacoma, Washington, Vereinigte Staaten, 98415
- MultiCare Health System
-
Wenatchee, Washington, Vereinigte Staaten, 98801
- Wenatchee Valley Hospital and Clinics
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Pathologically confirmed non-small cell lung cancer with documented EGFR mutation in tumor deoxyribonucleic acid (DNA) or complete/partial response to first line EGFR tyrosine kinase inhibitors with > or = to 6 months duration of response in patients who do not have a confirmed EGFR mutation
- At least one site of measurable disease as determined by the Investigator, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Progressive disease with radiographic evidence of disease progression per investigator assessment during therapy with an EGFR tyrosine kinase inhibitor in the metastatic setting; patients may continue EGFR inhibitor therapy throughout the screening period until the day prior to nab-paclitaxel treatment initiation
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 at the time of informed consent
- Platelet count >= 100,000/uL
- Absolute neutrophil count >= 1,500/uL
- Hemoglobin >= 9 g/dL
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 2.5 times upper limit of normal
- Alkaline phosphatase =< 2.5 times upper limit of normal, unless bone metastasis is present in the absence of liver metastasis
- Bilirubin =< 1.5 mg/dL
- Creatinine =< 1.5 mg/dL
- Women of child-bearing potential (WOCP) and sexually active men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry, during treatment and for three months after completing treatment
- Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of childbearing potential
- Life expectancy of > 12 weeks
- Signed and dated informed consent document indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrollment
Exclusion Criteria:
- Prior conventional cytotoxic chemotherapy for metastatic or recurrent disease; prior adjuvant, neoadjuvant or chemoradiotherapy for NSCLC is permitted, provided at least 6 months elapsed prior to documented metastatic recurrence
- A single dose of a platinum doublet discontinued due to intolerability without evidence of disease progression is permitted
- Patient is < 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active intervention
- Progressive or symptomatic central nervous system (CNS) metastases; patients with known brain metastasis must have stable disease following treatment with surgery, radiation or both; in addition, they must be off corticosteroids
- Radiotherapy within 7 days of study treatment
- Peripheral neuropathy grade 2 or greater
- Grade III/IV congestive heart failure, as defined by New York Heart Association (NYHA) criteria, or myocardial infarction within 6 months
- Any serious or uncontrolled concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study
- Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis or cirrhosis
- Major surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery
- Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent
- Pregnant or breast feeding females
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment (paclitaxel albumin-stabilized nanoparticle formula)
Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Korrelative Studien
Gegeben IV
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria
Zeitfenster: Assessed every two cycles from date of first study therapy until documented disease progression, date of death, unacceptable toxicity, or withdrawal of patient consent, whichever occurs first, assessed up to 60 weeks.
|
The response rate as the proportion and 95% confidence interval of patients who achieved a complete response or partial response will be calculated.
|
Assessed every two cycles from date of first study therapy until documented disease progression, date of death, unacceptable toxicity, or withdrawal of patient consent, whichever occurs first, assessed up to 60 weeks.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall Percentage of Patients Experiencing Toxicity Within a Clinically Significant Category Defined as Neutropenia, Neutropenic Fever, or Neuropathy.
Zeitfenster: Collected from the time patient received the first dose of study therapy through 30 days following the last dose of study therapy or the start of a new cancer therapy, whichever occurred first, assessed up to 64 weeks.
|
Toxicity rates will be described as percentage of patient who experienced a Grade 3 or higher clinically significant toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
|
Collected from the time patient received the first dose of study therapy through 30 days following the last dose of study therapy or the start of a new cancer therapy, whichever occurred first, assessed up to 64 weeks.
|
Overall Survival
Zeitfenster: Assessed from date of patient consent until date of death from any cause or withdrawal of patient consent, whichever occurs first, assessed up to 305 weeks.
|
Will report as median values with their respective 95% confidence intervals will be reported.
Time to event distribution will be estimated using Kaplan-Meier method.
|
Assessed from date of patient consent until date of death from any cause or withdrawal of patient consent, whichever occurs first, assessed up to 305 weeks.
|
Overall Percentage of Patients Experiencing Grade 3 or Higher Toxicity.
Zeitfenster: Collected from the time patient received the first dose of study therapy through 30 days following the last dose of study therapy or the start of a new cancer therapy, whichever occurred first, assessed up to 64 weeks.
|
Toxicity rates will be described as percentage of patients experiencing Grade 3 or higher toxicity according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
|
Collected from the time patient received the first dose of study therapy through 30 days following the last dose of study therapy or the start of a new cancer therapy, whichever occurred first, assessed up to 64 weeks.
|
Time to Progression.
Zeitfenster: Assessed from date of patient consent until documented disease progression, date of death from any cause, start of new anti-cancer therapy, or withdrawal of patient consent, whichever occurs first, assessed up to 60 weeks.
|
Reported as median values with their respective 95% confidence intervals for patients who were assessed.
Time to event distribution will be estimated using the Kaplan-Meier method.
|
Assessed from date of patient consent until documented disease progression, date of death from any cause, start of new anti-cancer therapy, or withdrawal of patient consent, whichever occurs first, assessed up to 60 weeks.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Christina Baik, Fred Hutch/University of Washington Cancer Consortium
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen der Atemwege
- Neubildungen
- Lungenkrankheit
- Neubildungen nach Standort
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Lungentumoren
- Karzinom, nicht-kleinzellige Lunge
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Antineoplastische Mittel, Phytogen
- Paclitaxel
- Albumingebundenes Paclitaxel
Andere Studien-ID-Nummern
- 7755 (Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (US NIH Stipendium/Vertrag)
- NCI-2012-00865 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- RG1712044 (Andere Kennung: Fred Hutch/University of Washington Cancer Consortium)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Rezidivierendes nicht-kleinzelliges Lungenkarzinom
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)AbgeschlossenExtranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem lymphatischem Gewebe | Nodales Marginalzonen-B-Zell-Lymphom | Rezidivierendes Burkitt-Lymphom bei Erwachsenen | Wiederkehrendes diffuses großzelliges Lymphom bei Erwachsenen | Rezidivierendes diffuses gemischtzelliges... und andere BedingungenVereinigte Staaten
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)AbgeschlossenWiederkehrende akute myeloische Leukämie bei Erwachsenen | Extranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem lymphatischem Gewebe | Nodales Marginalzonen-B-Zell-Lymphom | Rezidivierendes Burkitt-Lymphom bei Erwachsenen | Wiederkehrendes diffuses großzelliges Lymphom... und andere BedingungenVereinigte Staaten, Italien
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AbgeschlossenHIV infektion | Nicht näher bezeichneter solider Tumor im Kindesalter, protokollspezifisch | Primäre Myelofibrose | Polycythaemia Vera | Essentielle Thrombozythämie | Multiples Myelom im Stadium I | Multiples Myelom im Stadium II | Multiples Myelom im Stadium III | Chronische myelomonozytäre Leukämie und andere BedingungenVereinigte Staaten
-
Northwestern UniversitySeagen Inc.BeendetExtranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem lymphatischem Gewebe | Nodales Marginalzonen-B-Zell-Lymphom | Rezidivierendes Burkitt-Lymphom bei Erwachsenen | Rezidivierendes diffuses gemischtzelliges Lymphom bei Erwachsenen | Rezidivierendes diffuses kleinzelliges... und andere BedingungenVereinigte Staaten
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AbgeschlossenPrimäre Myelofibrose | Multiples Myelom im Stadium I | Multiples Myelom im Stadium II | Multiples Myelom im Stadium III | Wiederkehrende akute myeloische Leukämie bei Erwachsenen | Extranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem lymphatischem Gewebe | Nodales Marginalzonen-B-Zell-Lymphom und andere BedingungenVereinigte Staaten
-
National Cancer Institute (NCI)AbgeschlossenExtranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem lymphatischem Gewebe | Wiederkehrendes diffuses großzelliges Lymphom bei Erwachsenen | Rezidivierendes diffuses kleinzelliges Lymphom bei Erwachsenen | Rezidivierendes follikuläres Lymphom Grad 1 | Rezidivierendes follikuläres... und andere BedingungenVereinigte Staaten
-
University of NebraskaNational Cancer Institute (NCI)BeendetWiederkehrende akute myeloische Leukämie bei Erwachsenen | Extranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem lymphatischem Gewebe | Nodales Marginalzonen-B-Zell-Lymphom | Rezidivierendes Burkitt-Lymphom bei Erwachsenen | Wiederkehrendes diffuses großzelliges Lymphom... und andere BedingungenVereinigte Staaten
-
Case Comprehensive Cancer CenterBeendetExtranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem lymphatischem Gewebe | Nodales Marginalzonen-B-Zell-Lymphom | Rezidivierendes Burkitt-Lymphom bei Erwachsenen | Wiederkehrendes diffuses großzelliges Lymphom bei Erwachsenen | Rezidivierendes diffuses gemischtzelliges... und andere BedingungenVereinigte Staaten
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AbgeschlossenPrimäre Myelofibrose | Polycythaemia Vera | Essentielle Thrombozythämie | Multiples Myelom im Stadium I | Multiples Myelom im Stadium II | Multiples Myelom im Stadium III | Wiederkehrende akute myeloische Leukämie bei Erwachsenen | Extranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem... und andere BedingungenVereinigte Staaten, Italien
-
National Cancer Institute (NCI)AbgeschlossenExtranodales B-Zell-Lymphom der Randzone von Schleimhaut-assoziiertem lymphatischem Gewebe | Nodales Marginalzonen-B-Zell-Lymphom | Rezidivierendes Burkitt-Lymphom bei Erwachsenen | Wiederkehrendes diffuses großzelliges Lymphom bei Erwachsenen | Rezidivierendes diffuses gemischtzelliges... und andere BedingungenVereinigte Staaten
Klinische Studien zur Labor-Biomarker-Analyse
-
Vanderbilt University Medical Center4DMedicalAbgeschlossen
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Noch keine RekrutierungHIV-Infektionen | Hepatitis B
-
Duke UniversityZurückgezogenAntikoagulations- und Thrombose-Point-of-Care-Test (AT-POCT)Vereinigte Staaten
-
Columbia UniversityAbgeschlossen
-
McGill University Health Centre/Research Institute...Northwestern UniversityRekrutierungApnoe der FrühgeburtlichkeitKanada
-
Emory UniversityDermatology FoundationBeendetKutaner Lupus erythematodesVereinigte Staaten